financetom
Business
financetom
/
Business
/
Natural Gas Rises on Tightening Supply Despite Mild Forecasts
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Natural Gas Rises on Tightening Supply Despite Mild Forecasts
May 26, 2025 6:45 AM

09:26 AM EDT, 05/13/2025 (MT Newswires) -- Natural gas moved higher early on Tuesday on expectations supply will tighten even as long-term forecasts see little summer heat on the way to boost cooling demand.

Gas for June delivery was last seen up US$0.05 to US$3.70 per million British thermal units.

The rise comes as U.S. gas supplies are likely to weaken amid expectations oil drilling will slow as prices decline, lowering associated-gas production.

"We expect the crude market to tip into meaningful oversupply in H2'25 pushing WTI to or below $55/bbl in the back half of the year which, along with efficiency gains, will drive a meaningful drop in the US rig count (TPHe 95 oil-directed rigs), setting the stage for associated gas growth meaningfully decelerating," Tudor, Pickering, Holt analyst Matt Portillo wrote.

However mild long-term forecasts are checking prices, as the market waits on the arrival of summer heat that will boost cooling demand. The National Weather Service's six to 10 day outlook expects most states to see cooler than seasonal temperatures over the period, though Texas and other southern states will be warmer than seasonal.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows
Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows
Mar 6, 2024
ViiV Healthcare, majority owned by GSK Plc ( GSK ) , with Pfizer Inc ( PFE ) and Shionogi Limited as shareholders, revealed data from a planned interim analysis of the LATITUDE phase 3 trial. The data indicated that long-acting injectable antiretroviral treatment (ART) for HIV, Cabenuva (cabotegravir + rilpivirine), demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of...
Emergent BioSolutions Reports Q4 Results, Amends Credit Agreement
Emergent BioSolutions Reports Q4 Results, Amends Credit Agreement
Mar 6, 2024
Emergent Biosolutions Inc ( EBS ) shares are trading higher after the company amended its existing credit agreement and reported its fourth-quarter financial results. Here's a look at the details.  The Details: Emergent BioSolutions ( EBS ) reported quarterly losses of 77 cents per share, missing the analyst consensus estimate of losses of 19 cents per share. Quarterly sales came...
Five9 Insider Sold Shares Worth $2,715,680, According to a Recent SEC Filing
Five9 Insider Sold Shares Worth $2,715,680, According to a Recent SEC Filing
Mar 6, 2024
05:02 PM EST, 03/06/2024 (MT Newswires) -- Michael Burkland, Chief Executive Officer, on March 04, 2024, sold 46,447 shares in Five9 ( FIVN ) for $2,715,680. Following the Form 4 filing with the SEC, Burkland has control over a total of 411,495 shares of the company, with 278,469 shares held directly and 133,026 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1288847/000128884724000020/xslF345X03/wk-form4_1709762280.xml ...
--Hess Keeps Quarterly Dividend at $0.4375 Per Share; Payable March 28 to Shareholders of Record on March 18
--Hess Keeps Quarterly Dividend at $0.4375 Per Share; Payable March 28 to Shareholders of Record on March 18
Mar 6, 2024
04:42 PM EST, 03/06/2024 (MT Newswires) -- Price: 143.49, Change: +0.47, Percent Change: +0.33 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved